Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science

[Image: see text] Genome-wide association studies in patients revealed HSD17B13 as a potential new target for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. However, the physiological function and the disease-relevant substrate of HSD17B13 remain unknown. In addition,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thamm, Sven, Willwacher, Marina K., Aspnes, Gary E., Bretschneider, Tom, Brown, Nicholas F., Buschbom-Helmke, Silke, Fox, Thomas, Gargano, Emanuele M., Grabowski, Daniel, Hoenke, Christoph, Matera, Damian, Mueck, Katja, Peters, Stefan, Reindl, Sophia, Riether, Doris, Schmid, Matthias, Tautermann, Christofer S., Teitelbaum, Aaron M., Trünkle, Cornelius, Veser, Thomas, Winter, Martin, Wortmann, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969402/
https://www.ncbi.nlm.nih.gov/pubmed/36727857
http://dx.doi.org/10.1021/acs.jmedchem.2c01884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969402/
https://www.ncbi.nlm.nih.gov/pubmed/36727857
http://dx.doi.org/10.1021/acs.jmedchem.2c01884

Ejemplares similares